Lupus Erythematosus, Systemic Clinical Trial
Official title:
Association Between the Presence of Autoantibodies Targeting Ficolin-2 and Active Nephritis in Patients With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the
production of multiple autoantibodies. The prevalence and significance of antibodies against
Ficolin-2 have not been yet investigated. The aims of this study were to determine the
prevalence of anti-ficolin-2 antibodies among SLE patients and to investigate their
potential as diagnostic and/or prognostic biomarkers in SLE.
This study is a secondary phase of a serum sample analysis done in early 2015 in order to
determine the prevalence of anti-ficolin-2 antibodies among the same cohort as the
previously declared study (ClinicalTrials.gov ID: NCT02625831; Unique Protocol ID:
1841851v0).
In this retrospective study, clinical data were obtained from medical files and blood
samples were selected from preexisting biological collection. SLE patients (n=165) were
informed and did not objected, they were matched to healthy controls (n=48). Disease
activity was determined according to the SLEDAI score. Anti-ficolin-2 antibodies levels were
measured in sera by ELISA and correlated to previously obtained Anti-ficolin-3,
Anti-ficolin-2, anti-dsDNA and anti-C1q antibodies levels.
The titer of anti-ficolin-2 antibodies was correlated with the SLEDAI score (p<0.0001). The
presence of anti-ficolin-2 antibodies was associated with anti-ficolin-3 antibodies,
anti-C1q and anti-dsDNA antibodies.
Interestingly, the combination of anti-ficolin-3, anti-ficolin-2 and anti-C1q antibodies
demonstrated higher specificity than any other traditional biomarker.
These results suggest that anti-ficolin-3 and anti-ficolin-2 antibodies could be useful for
the diagnosis of active nephritis in SLE patients.
For this retrospective study, the well written brief summary should be sufficient. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
| Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
| Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
| Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
| Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
| Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
| Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
| Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
| Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
| Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
| Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
| Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
| Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
| Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
| Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|